Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Главный автор: | Flora, Sanzida Alam |
---|---|
Другие авторы: | Azam, Faruque |
Формат: | Диссертация |
Язык: | English |
Опубликовано: |
Brac University
2024
|
Предметы: | |
Online-ссылка: | http://hdl.handle.net/10361/23693 |
Схожие документы
-
A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
по: Khan, Muidul Hasan
Опубликовано: (2024) -
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
по: Paul, Pulock
Опубликовано: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
по: Rahman, Tasnim
Опубликовано: (2024) -
A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
по: Sorno, Rubina Haque
Опубликовано: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
по: Hoque, Ismoth Ara
Опубликовано: (2024)